Reproductive studies performed in mice and rats treated with linezolid showed no evidence of teratogenic effects. Mild fetal toxicity was observed in mice only at maternally toxic dose levels. In rats, fetal toxicity was manifested as decreased fetal body weights and reduced ossification of sternebrae (which is often seen in association with decreased body weights). Reduced pup survival and mild maturational delays occurred in rats. When mated, these same pups showed evidence of a reversible, dose-related increase in pre-implantation loss. There are no adequate and well-controlled studies in pregnant women. Therefore, linezolid should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Linezolid decreased the fertility of male rats.
Linezolid transferred into the breast milk of lactating laboratory rats. It is not known whether linezolid is excreted in human milk. Therefore, caution should be exercised when linezolid is administered to a nursing woman.